Qingdao Vland Biotech Co Ltd (603739) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.013x

Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) has a cash flow conversion efficiency ratio of 0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥24.29 Million ≈ $3.55 Million USD) by net assets (CN¥1.90 Billion ≈ $278.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Qingdao Vland Biotech Co Ltd balance sheet independence to measure how much of total assets are equity-financed.

Qingdao Vland Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Qingdao Vland Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Qingdao Vland Biotech Co Ltd (603739) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Qingdao Vland Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Qingdao Vland Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Design Therapeutics Inc
NASDAQ:DSGN
-0.056x
Better Home & Finance Holding Company
NYSE:BETR
-0.797x
Renxin New Material Co. Ltd. A
SHE:301395
N/A
First Tractor Company Limited
F:FTP
0.097x
Pan Asia Chemical Co
TWO:4707
0.017x
Universal Store Holdings Ltd
AU:UNI
0.352x
Shinhan Alpha REIT Co Ltd
KO:293940
0.005x
Vishnu Chemicals Limited
NSE:VISHNU
0.085x

Annual Cash Flow Conversion Efficiency for Qingdao Vland Biotech Co Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Qingdao Vland Biotech Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Qingdao Vland Biotech Co Ltd (603739) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.87 Billion
≈ $273.64 Million
CN¥195.41 Million
≈ $28.59 Million
0.104x +24.19%
2023-12-31 CN¥1.83 Billion
≈ $267.11 Million
CN¥153.59 Million
≈ $22.48 Million
0.084x +53.08%
2022-12-31 CN¥1.73 Billion
≈ $253.73 Million
CN¥95.31 Million
≈ $13.95 Million
0.055x +3.50%
2021-12-31 CN¥1.69 Billion
≈ $246.65 Million
CN¥89.51 Million
≈ $13.10 Million
0.053x -65.76%
2020-12-31 CN¥1.12 Billion
≈ $163.20 Million
CN¥173.00 Million
≈ $25.31 Million
0.155x +145.11%
2019-12-31 CN¥1.03 Billion
≈ $151.05 Million
CN¥65.33 Million
≈ $9.56 Million
0.063x -53.40%
2018-12-31 CN¥631.38 Million
≈ $92.39 Million
CN¥85.75 Million
≈ $12.55 Million
0.136x -33.98%
2017-12-31 CN¥592.53 Million
≈ $86.71 Million
CN¥121.90 Million
≈ $17.84 Million
0.206x -25.70%
2016-12-31 CN¥557.97 Million
≈ $81.65 Million
CN¥154.49 Million
≈ $22.61 Million
0.277x +93.62%
2015-12-31 CN¥519.36 Million
≈ $76.00 Million
CN¥74.27 Million
≈ $10.87 Million
0.143x +13.88%
2014-12-31 CN¥466.26 Million
≈ $68.23 Million
CN¥58.55 Million
≈ $8.57 Million
0.126x --

About Qingdao Vland Biotech Co Ltd

SHG:603739 China Biotechnology
Market Cap
$430.61 Million
CN¥2.94 Billion CNY
Market Cap Rank
#13010 Global
#3835 in China
Share Price
CN¥11.63
Change (1 day)
+1.04%
52-Week Range
CN¥10.81 - CN¥16.74
All Time High
CN¥58.91
About

Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more